A double-blind randomised, placebo-controlled trial evaluating the influence of oral long-acting muscle relaxant (Mebeverine MR), and insufflation with CO(2) on pain associated with barium enema.
Previous investigators have shown significant benefit using CO(2) for bowel insufflation. Others have suggested that the long-acting smooth muscle relaxant, Mebeverine, may be of benefit. We subjected this to a randomised double-blind trial. A total of 181 outpatients were randomised to receive either Mebeverine or placebo as pre-medication, and either air or CO(2) for bowel insufflation, thus creating four treatment groups. Visual-analogue lines were used to record pain scores before, during, and up to 8 h following the enema. All groups showed increased pain scores during the enema, with peak pain scores at the end of the examination, falling to baseline scores by 8 h. Patients receiving the combination of C0(2) and placebo had significantly lower pain scores at 1 and 4 h ( P=0.00 and P=0.014, respectively; Kruskal-Wallis test) compared with all other groups. Having Mebeverine as a pre-medication did not significantly lower pain scores compared with placebo, and decreased the amount of benefit received from the CO(2). We confirm that CO(2) is of benefit in decreasing pain during barium enema, and we recommend its routine use to improve the comfort of patients. Mebeverine is not of benefit, and its use as a pre-medication for enemas is not recommended.
Lowe
A S
AS
Department of Radiology, St James's University Hospital, Beckett Street, LS9 7TF, Leeds, UK. andylowe@doctors.org.uk
Chapman
A H
AH
Wilson
D
D
Culpan
A G
AG
D000284:Administration, Oral; D001466:Barium Sulfate; D002245:Carbon Dioxide; D004311:Double-Blind Method; D004733:Enema; D005260:Female; D006801:Humans; D007327:Insufflation; D008297:Male; D010146:Pain / Q000517:prevention & control*; D010147:Pain Measurement; D010276:Parasympatholytics / Q000008:administration & dosage* / Q000627:therapeutic use; D010627:Phenethylamines / Q000008:administration & dosage* / Q000627:therapeutic use
D010276:Parasympatholytics; D010627:Phenethylamines; D002245:Carbon Dioxide; D001466:Barium Sulfate; C005096:mebeverine